CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
Go back to CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)| Eaton Vance Dividend Builder Fd Cl C (NASDAQ: CTMX) | Delayed: 2.76 -0.06 (2.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.82 | 52 Week High | $24.68 | |||
| Open | $2.83 | 52 Week Low | $9.10 | |||
| Day High | $2.86 | P/E | N/A | |||
| Day Low | $2.72 | EPS | $0.00 | |||
| Volume | 9,597,041 | |||||
